Sign In
Buy ONCY
$0.94
+0.0237 (+2.58%)
At Close: Jun 23, 2026
Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference
07:00am, Wednesday, 28'th Feb 2024
SAN DIEGO and CALGARY, AB , Feb. 28, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that C
Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments
08:00am, Thursday, 15'th Feb 2024
Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - February 15, 2024) - Investorideas.com, a global investor news source covering biotech and pharma stocks issues a sector snapshot on c
Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort
07:00am, Wednesday, 14'th Feb 2024
Successful Stage 1 data showed a near tripling of Objective Response Rate compared to checkpoint inhibitor monotherapy, including a Complete Response, and supports expansion SAN DIEGO and CALGARY, Al
Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors
07:00am, Tuesday, 09'th Jan 2024
SAN DIEGO and CALGARY, AB , Jan. 9, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the app
Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024
07:00am, Thursday, 04'th Jan 2024
SAN DIEGO, CA and CALGARY, AB, Jan. 4, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, reported on signifi
Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS
07:00am, Thursday, 07'th Dec 2023
Pelareorep induced prominent expansion of pre-existing Tumor Infiltrating Lymphocytes (TILs) in the blood and new TILs in the tumor Data highlights the association between the expansion of existing TI
Oncolytics Biotech Inc. (ONCY) Q3 2023 Earnings Call Transcript
09:05pm, Friday, 03'rd Nov 2023
Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q3 2023 Earnings Conference Call November 3, 2023 8:30 AM ET Company Participants Jon Patton - Director, IR Matt Coffey - President & CEO Thomas Heineman - Chief
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights
07:00am, Friday, 20'th Oct 2023
Conference call and webcast to take place on Friday, November 3, 2023, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Oct. 20, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a
3 Under-$20 Stocks to Buy for Explosive Returns
07:00am, Monday, 21'st Aug 2023
A handful of stocks to buy under $20 can offer investors explosive returns in uncertain market conditions. The article lists names that might not immediately grab headlines, but their strategic focus
After Plunging -29.54% in 4 Weeks, Here's Why the Trend Might Reverse for Oncolytics Biotech Inc. (ONCY)
11:02am, Thursday, 17'th Aug 2023
The heavy selling pressure might have exhausted for Oncolytics Biotech Inc. (ONCY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall St
Oncolytics Biotech Inc. (ONCY) Q2 2023 Earnings Call Transcript
11:48am, Monday, 14'th Aug 2023
Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q2 2023 Earnings Conference Call August 14, 2023 8:30 AM ET Company Participants Jon Patton - Director-Investor Relations and Communications Matt Coffey - Presid
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights
07:00am, Friday, 04'th Aug 2023
Conference call and webcast to take place on Monday, August 14, 2023, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Aug. 4, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) toda
Oncolytics: Proof Of Concept In 2 Large Market Indications
05:39pm, Monday, 03'rd Jul 2023
Positive results achieved, in using pelareorep + paclitaxel for the treatment of HR+/HER2- metastatic breast cancer patients, in the phase 2 BRACELET-1 study. Preparation is underway to initiate a pha
Oncolytics Biotech's stock soars 25% after pelareorep is selected for inclusion in late-stage pancreatic cancer trial
01:12pm, Thursday, 22'nd Jun 2023
The stock of Oncolytics Biotech Inc. ONCY, +23.25% soared 25% Thursday, after the San Diego-based company said its pelareorep therapy has been selected for inclusion in a an adaptive phase 3 pancreati
Oncolytics Biotech Inc. (ONCY) Q1 2023 Earnings Call Transcript
12:37pm, Friday, 05'th May 2023
Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q1 2023 Earnings Conference Call May 5, 2023 8:30 AM ET Company Participants Jon Patton – Director-Investor Relations and Communications Matt Coffey – Chief
